Loading...

MedXY AI/MedXY News/Tag: oncology

MedXY News

EnglishTag

oncology

85 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC

Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC

The CAPItello-281 trial shows that capivasertib plus abiraterone improves radiographic progression-free survival by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer, highlighting the importance of biomarker-driven t

Section: newsJan 9, 2026

Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer

Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer

The CITRINE trial demonstrates that adding adjuvant carboplatin to standard chemotherapy significantly improves survival in high-risk triple-negative breast cancer patients, primarily by preventing early recurrence.

Section: news

Jan 9, 2026

High Ultra-Processed Food Consumption Linked to Increased Mortality Among Black Breast Cancer Survivors

High Ultra-Processed Food Consumption Linked to Increased Mortality Among Black Breast Cancer Survivors

A longitudinal study of 1,733 Black breast cancer survivors reveals that high intake of ultra-processed foods significantly increases both breast cancer-specific and all-cause mortality, highlighting a critical modifiable risk factor for ad

Section: newsJan 9, 2026

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer

A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of

Section: GastroenterologyJan 9, 2026

Industrial Food Preservatives Linked to Increased Cancer Risk: Evidence from the NutriNet-Santé Prospective Cohort

Industrial Food Preservatives Linked to Increased Cancer Risk: Evidence from the NutriNet-Santé Prospective Cohort

A large-scale prospective study of over 100,000 participants identifies significant associations between specific food preservatives, including sorbates, nitrites, and nitrates, and an increased risk of overall, breast, and prostate cancers

Section: newsJan 8, 2026

2025 FDA Drug Approvals: A Critical Review of New Therapeutic Frontiers and Regulatory Shifts

2025 FDA Drug Approvals: A Critical Review of New Therapeutic Frontiers and Regulatory Shifts

A comprehensive analysis of the 46 novel drugs approved by the FDA in 2025, highlighting breakthroughs in oncology, chronic pain, and respiratory medicine, alongside significant regulatory changes and a preview of the 2026 pipeline.

Section: Internal MedicineJan 8, 2026

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Ambulatory Cancer Patients

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Ambulatory Cancer Patients

A post hoc analysis of the AVERT trial identifies GDF-15, NT-proBNP, CRP, and hs-TnT as significant predictors for venous thromboembolism and bleeding in cancer patients, offering new tools for personalized risk stratification.

Section: CardiologyJan 6, 2026

Ideal Cardiovascular Health Scores Linked to 38% Lower Mortality in Cancer Survivors: Insights from the Moli-sani Study

Ideal Cardiovascular Health Scores Linked to 38% Lower Mortality in Cancer Survivors: Insights from the Moli-sani Study

A longitudinal study of cancer survivors reveals that those maintaining ideal cardiovascular health, measured by the Life’s Simple 7 metric, significantly reduce their risk of all-cause and cancer-specific mortality through pathways involvi

Section: CardiologyJan 5, 2026

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immu

Section: Diabetes & EndocrinologyDec 29, 2025

Beyond a Symptom: Baseline Fatigue as a Clinical Biomarker for Severe and Fatal Cancer Treatment Toxicities

Beyond a Symptom: Baseline Fatigue as a Clinical Biomarker for Severe and Fatal Cancer Treatment Toxicities

A large-scale pooled analysis of 17 SWOG trials demonstrates that baseline patient-reported fatigue significantly increases the risk of severe, life-threatening, and fatal toxic effects from systemic cancer therapy, highlighting its role as

Section: Hematology-OncologyDec 29, 2025

Survival in Cancer Patients with ARDS: The YELENNA Study Challenges ECMO Utility in Severe Cases

Survival in Cancer Patients with ARDS: The YELENNA Study Challenges ECMO Utility in Severe Cases

The YELENNA prospective study reveals a 73.2% 90-day mortality rate for cancer patients with ARDS. Crucially, venovenous ECMO provided no survival benefit in severe cases, prompting a re-evaluation of current clinical guidelines and goals-o

Section: Critical CareDec 27, 2025

Cervical Stromal Involvement and Morphology Redefine LG-ESS Prognosis: Why Radiotherapy May Not Be the Answer

Cervical Stromal Involvement and Morphology Redefine LG-ESS Prognosis: Why Radiotherapy May Not Be the Answer

Recent studies on Low-Grade Endometrial Stromal Sarcoma (LG-ESS) identify cervical stromal involvement as a key prognostic marker and suggest that adjuvant radiotherapy offers no survival benefit, advocating for individualized, risk-adapted

Section: newsDec 25, 2025

Rethinking Radical Surgery: Lobectomy Matches Total Thyroidectomy Outcomes in Intermediate-Risk PTC with Unilateral N1b Disease

Rethinking Radical Surgery: Lobectomy Matches Total Thyroidectomy Outcomes in Intermediate-Risk PTC with Unilateral N1b Disease

A comprehensive meta-analysis suggests that for intermediate-risk papillary thyroid carcinoma with unilateral lateral lymph node metastasis, lobectomy provides oncological outcomes comparable to total thyroidectomy, challenging the necessit

Section: General SurgeryDec 24, 2025

Occupation Matters: New Data Reveal Wide Disparities in US Cancer Mortality Among Working-Age Adults

Occupation Matters: New Data Reveal Wide Disparities in US Cancer Mortality Among Working-Age Adults

A comprehensive population study of 450,453 deaths identifies specific occupations, including fishing, mining, and funeral services, with disproportionately high cancer mortality, suggesting a complex interplay of workplace exposures and st

Section: newsDec 23, 2025

Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial

Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial

The E2C2 trial demonstrates that integrating electronic health record (EHR)-facilitated collaborative care with symptom surveillance significantly reduces the burden of anxiety, depression, and fatigue in oncology patients compared to surve

Section: Hematology-OncologyDec 23, 2025

Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care

Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care

A critical review of 29 breast cancer registrational trials reveals a significant gap in biomarker research dissemination, prompting a call for mandatory data and biospecimen sharing to accelerate personalized oncology and honor patient con

Section: Hematology-OncologyDec 23, 2025

Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC

Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC

A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate

Section: newsDec 23, 2025

Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer

Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer

A prospective cohort study demonstrates that a structured shared decision-making (SOP) model significantly increases the utilization of multidisciplinary palliative care services for patients with stage IV oral cavity cancer, bridging the g

Section: newsDec 22, 2025

Rising Immunotherapy Use at Cancer End of Life Is Linked to More Hospital-Based Care: What Clinicians Need to Know

Rising Immunotherapy Use at Cancer End of Life Is Linked to More Hospital-Based Care: What Clinicians Need to Know

In a population-based Ontario study, use of systemic anticancer therapy (SACT) in the last 30 days of life increased—driven by immunotherapy—and was associated with higher emergency visits, hospitalizations, ICU admissions, and hospital dea

Section: Hematology-OncologyDec 14, 2025

Clinical Benefit—not Billing Margin—Drives Oncologists’ Treatment Choices in Medicare Cohort

Clinical Benefit—not Billing Margin—Drives Oncologists’ Treatment Choices in Medicare Cohort

In a population-based Medicare cohort, oncologists preferentially selected higher-clinical-benefit cancer treatments; provider billing margin was not associated with treatment choice, suggesting price or payment reforms that change margins

Section: Hematology-OncologyNov 23, 2025

Prev 1 2 3 4 5 Next

MedXY News - oncology